News
Public · Published
Neurocrine climbs after Q3 beat, guidance hike
Neurocrine Biosciences reported third-quarter revenue of $1.1 billion, up about 41% year over year and $80 million above consensus, while non-GAAP earnings per share reached $3.29. It raised its 2026 Ingrezza sales outlook to $2.9 billion–$2.925 billion from $2.83 billion–$2.88 billion.
Published:
Updated:
What happened
Neurocrine Biosciences reported third-quarter revenue of $1.1 billion, up about 41% year over year and $80 million above consensus, while non-GAAP earnings per share reached $3.29. It raised its 2026 Ingrezza sales outlook to $2.9 billion–$2.925 billion from $2.83 billion–$2.88 billion.
Confirmed
Global impact / market context
Higher sales expectations for Ingrezza, alongside reported strength in Crenessity and Vykat, point to revenue growth from several products rather than reliance on one therapy alone. If that pattern continues, it could support future sales and reduce the business impact of slower growth in any single product.
Analyst inference
The reported share gain followed a third consecutive quarter in which revenue and earnings both exceeded estimates. The raised Ingrezza outlook also topped the cited consensus forecast, while analysts maintained positive ratings; these facts describe the reported context, not a guarantee of further share gains.
Confirmed
What to watch
- Check whether Neurocrine reports continued sales growth for Ingrezza and whether results meet or exceed its revised 2026 outlook of $2.9 billion–$2.925 billion. Analyst inference
- Look for further disclosures on Crenessity and Vykat sales; the article says these products together made up 28% of third-quarter revenue. Confirmed
- Compare future results with analyst expectations and watch for any change in the sales outlook, since a shortfall could weaken revenue growth expectations. Analyst inference